Idarubicin 10 mg/10 ml, 1, Accord

These drugs are inserted into DNA and act on an enzyme called topoisomerase II, which stops nucleic acid synthesis.
Idarubicin is a medicine used to treat the following conditions:
adults
To induce remission in untreated patients or to induce remission in patients with relapsed or refractory acute myelogenous leukemia (AML).
As a second-line therapy in patients with recurrent acute lymphocytic leukemia (ALL).
children
Acute myelogenous leukemia (AML) in combination with cytarabine to induce remission in untreated patients.
As a second-line therapy in patients with acute lymphocytic leukemia (ALL).
Idarubicin can also be used in combination with other anticancer drugs.
contraindication
Idarubicin should not be used
if you are allergic (hypersensitive) to idarubicin or any of the other ingredients of this medicine;
if you are allergic to other anthracyclines or anthracenediones;
if you have severely reduced liver function;
if you have severely reduced kidney function;
if you have heart problems;
if your body does not produce enough red blood cells, white blood cells, and platelets;
if you have previously been treated with idarubicin and/or other anthracycline lines or anthracenediones;
if you are breastfeeding.
Dosage of Idarubicin Accord 10 mg/10 ml solution for injection
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Dosage is calculated based on body surface area (mg/m 2 ).
Acute myelogenous leukemia
Adults: in acute myelogenous leukemia, the recommended dose is 12 mg/m 2 IV daily for 3 days in combination with cytarabine. Another dosing regimen that can be used for acute myelogenous leukemia, either as monotherapy or as part of combination therapy, is 8 mg/m 2 IV daily for 5 consecutive days.
Children: The recommended dose range is 10–12 mg/m 2 IV daily for 3 days in combination with cytarabine.
Acute lymphocytic leukemia
Adults: when used as monotherapy for acute myelogenous leukemia, the recommended dose is 12 mg/m 2 IV daily for 3 days.
Children: The recommended dose as monotherapy for acute myelogenous leukemia is 10 mg/m 2 IV daily for 3 days.
These dosing regimens should take into account the patient’s blood condition and, when used in combination, the doses of other cytotoxic drugs.
If you got more than you should
Very large single doses of idarubicin can cause acute damage to the heart muscle within the first 24 hours and severely impair the production of blood cells in the bone marrow within one to two weeks.
Late onset heart failure has been observed with anthracyclines used within a few months of an overdose.
If you forgot the application
Do not use a double dose if you have forgotten the previous use.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
patient records
Warnings and Precautions
If you have heart problems. Before starting treatment with idarubicin, cardiac function should be assessed and monitored during treatment to minimize the risk of serious damage to the heart;
if you have impaired bone marrow function and low levels of red blood cells, white blood cells, and platelets;
if you have a persistent and significant increase in the number of abnormal white blood cells in your blood. You may develop leukemia;
if you have problems with the gastrointestinal tract;
if you have liver problems;
if you have kidney problems;
This medicine may cause vomiting, sore throat, or sores in the lining of the digestive tract;
you may develop reactions at the injection site;
leakage of fluid into the surrounding tissues during the injection (extravasation) can cause pain, and extravasation can also cause severe tissue damage. If extravasation occurs, the administration of the drug should be stopped immediately;
as in the case of other cytotoxic substances, inflammation of the vascular wall with the formation of blood clots may occur;
if you have recently been vaccinated or plan to be vaccinated;
if you are a man, idarubicin can cause permanent infertility.
Idarubicin should only be administered under the supervision of a physician experienced in cytotoxic chemotherapy.
This medicine may cause urine to turn red for 1 to 2 days after ingestion.
Your blood, liver, kidneys, and heart will be checked regularly before and during your treatment with idarubicin. Infants and children appear to be more susceptible to anthracycline-induced cardiac injury. Therefore, such patients need to regularly check the function of the heart over a long period of time.
Ability to drive and use machines
Systematic studies of the effect of idarubicin on the ability to drive a car and work with mechanisms have not been conducted.